Premium
[P1–069]: OPTIMIZING MEASUREMENT OF AGITATION AND AGGRESSION IN DEMENTIA
Author(s) -
Hendrix Suzanne,
Brown Bruce L.,
Cummings Jeffrey L.,
Lyketsos Constantine,
Porsteinsson Anton P.,
Rosenberg Paul B.,
Sano Mary
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.06.136
Subject(s) - placebo , aggression , psychology , risperidone , alzheimer's disease , analysis of variance , dementia , clinical psychology , medicine , psychiatry , disease , schizophrenia (object oriented programming) , pathology , alternative medicine
cog11 scale after 48 weeks of treatment was 3.45 points for the donepezil alone arm and 1.80 points for the 35 mg intepirdine in conjunction with donepezil arm. This difference in the magnitude of cognitive decline over 48 weeks was statistically significant (p 1⁄4 0.024). Subjects who received 35 mg intepirdine in conjunction with donepezil experienced 47.7% less decline from baseline to week 48 than subjects who received donepezil alone. Conclusions: In this study of 684 subjects with mild to moderate AD, 35 mg intepirdine in conjunction with donepezil resulted in 47.7% less decline over 48 weeks compared to donepezil alone. Further research is warranted to better characterize this effect.